Marcello Arca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8993618/publications.pdf

Version: 2024-02-01

178	8,412	44066	56717
papers	citations	48 h-index	83 g-index

187	187	187	9049
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein. Science, 2001, 292, 1394-1398.	12.6	539
2	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	27.0	510
3	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	27.0	359
4	Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment. Circulation, 2005, 111, 278-287.	1.6	302
5	PREVALENCE OF GALLSTONE DISEASE IN AN ITALIAN ADULT FEMALE POPULATION. American Journal of Epidemiology, 1984, 119, 796-805.	3.4	249
6	A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke. JAMA - Journal of the American Medical Association, 2004, 291, 2221.	7.4	227
7	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
8	The Molecular Basis of Lecithin:Cholesterol Acyltransferase Deficiency Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1972-1978.	2.4	158
9	The Gln-Arg192 Polymorphism of Human Paraoxonase Gene Is Not Associated With Coronary Artery Disease in Italian Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1611-1616.	2.4	155
10	Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet, The, 2002, 359, 841-847.	13.7	150
11	Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1706-1713.	2.4	141
12	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€• Atherosclerosis, 2018, 275, 265-272.	0.8	131
13	Mutations in theANGPTL3Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1266-E1275.	3.6	126
14	Association of the human adiponectin gene and insulin resistance. European Journal of Human Genetics, 2004, 12, 199-205.	2.8	124
15	The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age â‰50 years). Journal of Molecular Medicine, 2005, 83, 711-719.	3.9	119
16	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	11.4	114
17	Human Resistin Gene, Obesity, and Type 2 Diabetes: Mutation Analysis and Population Study. Diabetes, 2002, 51, 860-862.	0.6	113
18	Molecular mechanisms of autosomal recessive hypercholesterolemia. Human Molecular Genetics, 2002, 11, 3019-3030.	2.9	101

#	Article	IF	Citations
19	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	1.5	97
20	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation, 2010, 121, 52-62.	1.6	96
21	Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans. Circulation, 2009, 120, 628-635.	1.6	94
22	Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison. Atherosclerosis, 2006, 188, 398-405.	0.8	84
23	Characterization of a New Form of Inherited Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 802-809.	2.4	83
24	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
25	Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: Reduction during atorvastatin and fenofibrate therapy. Free Radical Biology and Medicine, 2007, 42, 698-705.	2.9	82
26	99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 117-126.	6.4	78
27	A Common Mutation of the Insulin Receptor Substrate-1 Gene Is A Risk Factor for Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2975-2980.	2.4	76
28	Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis. Current Vascular Pharmacology, 2012, 10, 684-686.	1.7	76
29	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Journal of Lipid Research, 2013, 54, 3481-3490.	4.2	76
30	Clinical and genetic characterization of Chanarinâ€“Dorfman syndrome. Biochemical and Biophysical Research Communications, 2008, 369, 1125-1128.	2.1	72
31	Management of metabolic syndrome in children and adolescents. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 455-466.	2.6	70
32	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
33	The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. Gene, 2015, 555, 23-32.	2.2	67
34	Usefulness of Atherogenic Dyslipidemia for Predicting Cardiovascular Risk in Patients With Angiographically Defined Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 1511-1516.	1.6	65
35	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
36	Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans. Circulation, 2009, 120, 628-635.	1.6	63

#	Article	IF	Citations
37	The G972R variant of the Insulin Receptor Substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia, 2001, 44, 367-372.	6.3	61
38	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	3.3	59
39	Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochemical and Biophysical Research Communications, 2008, 377, 843-846.	2.1	58
40	Treating statin-intolerant patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 155.	2.4	58
41	PON1ÂL55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. European Journal of Clinical Investigation, 2002, 32, 9-15.	3.4	57
42	The common PPAR-Î³2 Pro12Ala variant is associated with greater insulin sensitivity. European Journal of Human Genetics, 2004, 12, 1050-1054.	2.8	57
43	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	2.9	56
44	Subclinical Atherosclerosis in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 661-668.	2.4	54
45	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
46	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. Journal of Cardiovascular Medicine, 2021, 22, 151-161.	1.5	53
47	Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. Journal of Clinical Lipidology, 2021, 15, 68-78.	1.5	52
48	Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. Clinical Science, 2015, 129, 963-972.	4.3	51
49	Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients. Orphanet Journal of Rare Diseases, 2017, 12, 90.	2.7	49
50	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. Journal of Lipid Research, 2016, 57, 1097-1107.	4.2	48
51	Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function. Human Molecular Genetics, 2012, 21, 5318-5328.	2.9	47
52	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. Scientific Reports, 2017, 7, 15756.	3.3	45
53	Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Medical Genetics, 2003, 4, 8.	2.1	44
54	High <scp>TG</scp> to <scp>HDL</scp> ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes/Metabolism Research and Reviews, 2021, 37, e3367.	4.0	44

#	Article	IF	Citations
55	The G-308A variant of the Tumor Necrosis Factor-Î± (TNF-Î±) gene is not associated with obesity, insulin resistance and body fat distribution. BMC Medical Genetics, 2001, 2, 10.	2.1	42
56	Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs, 2007, 67, 29-42.	10.9	41
57	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.8	39
58	Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2531-2541.	2.4	39
59	Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288.	2.8	38
60	Association of Hypertriglyceridemia with Allâ€Cause Mortality and Atherosclerotic Cardiovascular Events in a Lowâ€Risk Italian Population: The TGâ€REAL Retrospective Cohort Analysis. Journal of the American Heart Association, 2020, 9, e015801.	3.7	38
61	Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clinical Genetics, 2001, 60, 374-380.	2.0	37
62	Haemochromatosis gene mutations and risk of coronary artery disease. European Journal of Human Genetics, 2000, 8, 389-392.	2.8	36
63	Molecular imaging in atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2381-2397.	6.4	35
64	The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Review of Cardiovascular Therapy, 2018, 16, 537-546.	1.5	35
65	Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: Results of a family and DNA-based screening. Atherosclerosis, 2008, 196, 356-364.	0.8	34
66	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: AÂcomparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. Journal of Clinical Lipidology, 2017, 11, 1234-1242.	1.5	34
67	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 197-205.	2.6	34
68	Hypercholesterolemia in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1994, 271, 453.	7.4	32
69	The angiopoietin-like protein 3. Current Opinion in Lipidology, 2013, 24, 313-320.	2.7	32
70	Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. International Journal of Molecular Sciences, 2019, 20, 4444.	4.1	32
71	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 2019, 3, 2397-2410.	0.2	32
72	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Advances in Therapy, 2020, 37, 1724-1736.	2.9	32

#	Article	IF	Citations
73	Adaptor Protein ARH Is Recruited to the Plasma Membrane by Low Density Lipoprotein (LDL) Binding and Modulates Endocytosis of the LDL/LDL Receptor Complex in Hepatocytes. Journal of Biological Chemistry, 2005, 280, 38416-38423.	3.4	31
74	Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 704-711.e2.	1.5	31
75	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.8	31
76	Atorvastatin Efficacy in the Prevention of Cardiovascular Events in Patients with Diabetes Mellitus and/or Metabolic Syndrome. Drugs, 2007, 67, 43-54.	10.9	30
77	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3340-3348.	3.6	29
78	Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 665-674.	2.4	29
79	Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene. Biochemical and Biophysical Research Communications, 2013, 430, 241-244.	2.1	28
80	Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency. Current Opinion in Lipidology, 2020, 31, 41-48.	2.7	28
81	C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 752-757.	2.4	27
82	Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. Atherosclerosis, 2009, 207, 162-167.	0.8	27
83	Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatric Research, 2019, 85, 671-677.	2.3	27
84	Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia. Archives of Internal Medicine, 1991, 151, 146.	3.8	26
85	Congenital Analbuminemia attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene. Clinical Chemistry, 2005, 51, 1256-1258.	3.2	26
86	Mutations in the HFE Gene and Cardiovascular Disease Risk. Circulation: Cardiovascular Genetics, 2008, 1, 43-50.	5.1	26
87	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports, 2020, 22, 18.	4.8	26
88	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. International Journal of Molecular Sciences, 2021, 22, 7193.	4.1	26
89	The common mutations in the lipoprotein lipase gene in Italy: effects on plasma lipids and angiographically assessed coronary atherosclerosis. Clinical Genetics, 2000, 58, 369-374.	2.0	25
90	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. Clinical Epigenetics, 2019, 11, 151.	4.1	25

#	Article	IF	Citations
91	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.8	25
92	Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1010-1016.	2.6	24
93	Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Longâ€Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. Journal of the American Heart Association, 2021, 10, e018932.	3.7	24
94	Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients. European Journal of Clinical Investigation, 1998, 28, 485-490.	3.4	23
95	Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1540-E1548.	3.6	23
96	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. European Journal of Internal Medicine, 2014, 25, 566-570.	2.2	23
97	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). Atherosclerosis, 2017, 263, e10.	0.8	23
98	Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. International Journal of Cardiology, 2020, 316, 229-235.	1.7	23
99	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology, 2022, 29, 832-841.	1.8	23
100	Plasma and erythrocyte fatty acids: A methodology for evaluation of hypocholesterolemic dietary interventions. Preventive Medicine, 1983, 12, 124-127.	3.4	22
101	ApoCIII: A multifaceted protein in cardiometabolic disease. Metabolism: Clinical and Experimental, 2020, 113, 154395.	3.4	22
102	Autosomal recessive hypercholesterolemia: update for 2020. Current Opinion in Lipidology, 2020, 31, 56-61.	2.7	22
103	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	6.0	21
104	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	3.2	21
105	The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?. International Journal of Molecular Sciences, 2021, 22, 742.	4.1	21
106	Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. Molecular Genetics and Metabolism, 2007, 92, 243-248.	1.1	20
107	Low density lipoprotein receptor mutations in a selected population of individuals with moderate hypercholesterolemia. Atherosclerosis, 1998, 136, 187-194.	0.8	19
108	The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 407-413.	2.6	19

#	Article	IF	Citations
109	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterolâ€“diabetes connection? A systematic review of literature. Acta Diabetologica, 2017, 54, 111-122.	2.5	19
110	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€“therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.1	19
111	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. Journal of Lipid Research, 2020, 61, 1784-1788.	4.2	19
112	Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. Metabolism: Clinical and Experimental, 1991, 40, 1074-1078.	3.4	18
113	Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism: Clinical and Experimental, 2007, 56, 1534-1541.	3.4	18
114	Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis. Journal of Lipids, 2013, 2013, 1-7.	4.8	18
115	Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach. Atherosclerosis, 2015, 242, 618-624.	0.8	18
116	A Novel Mutation in ABCA1 Gene Causing Tangier Disease in an Italian Family with Uncommon Neurological Presentation. Frontiers in Neurology, 2016, 7, 185.	2.4	18
117	Analysis of Children and Adolescents with Familial Hypercholesterolemia. Journal of Pediatrics, 2017, 183, 100-107.e3.	1.8	18
118	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. Journal of Lipid Research, 2017, 58, 994-1001.	4.2	18
119	Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate[ndash]1, the [beta]3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism: Clinical and Experimental, 2002, 51, 1298-1305.	3.4	17
120	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1675-1684.	1.8	17
121	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe â€“ Methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus, 2021, 43, 24-30.	0.7	17
122	Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH). Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 278-286.	2.6	16
123	Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome. Atherosclerosis Supplements, 2015, 17, 12-16.	1.2	16
124	A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family. Biochemical and Biophysical Research Communications, 2019, 508, 487-493.	2.1	16
125	CT texture-based radiomics analysis of carotid arteries identifies vulnerable patients: a preliminary outcome study. Neuroradiology, 2021, 63, 1043-1052.	2.2	16
126	Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS). Current Atherosclerosis Reports, 2021, 23, 65.	4.8	16

#	Article	IF	Citations
127	Atorvastatin. Drugs, 2007, 67, 55-62.	10.9	15
128	Atorvastatin. Drugs, 2007, 67, 63-69.	10.9	15
129	Imaging coronary and extracoronary atherosclerosis: feasibility and impact of whole-body computed tomography angiography. European Radiology, 2009, 19, 1704-1714.	4.5	15
130	Plasma Nonâ€“cholesterol Sterols: A Useful Diagnostic Tool in Pediatric Hypercholesterolemia. Pediatric Research, 2010, 67, 200-204.	2.3	15
131	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis. International Journal of Cardiology, 2013, 168, 4375-4378.	1.7	15
132	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2301-2308.	3.9	15
133	Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart, 2023, 109, 18-25.	2.9	15
134	Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. American Journal of Medicine, 2004, 117, 803-804.	1.5	14
135	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 991-997.	2.4	14
136	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Failure Clinics, 2021, 18, 177-188.	2.1	14
137	Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study. European Heart Journal, 1992, 13, 11-16.	2.2	13
138	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. Journal of Cardiovascular Medicine, 2018, 19, 83-90.	1.5	13
139	ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: findings from the Moli-family cohort. Clinical Epigenetics, 2019, 11, 74.	4.1	12
140	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	2.7	12
141	Twelve Variants Polygenic Score for Lowâ€Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	3.7	12
142	Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. PLoS ONE, 2015, 10, e0120099.	2.5	11
143	Neutral lipidâ€storage disease with myopathy and extended phenotype with novel PNPLA2 mutation. Muscle and Nerve, 2016, 53, 644-648.	2.2	11
144	Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2027-2035.	2.6	11

#	Article	IF	Citations
145	Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment. Journal of Hypertension, 2016, 34, 567-587.	0.5	10
146	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. Atherosclerosis Supplements, 2020, 42, e35-e40.	1.2	10
147	Plasma cholesterol response to a change in dietary fat intake: A collaborative twin study. Journal of Chronic Diseases, 1985, 38, 927-934.	1.2	9
148	Heritability, genetic correlation and linkageÂto the 9p21.3 region of mixed plateletâ€“leukocyte conjugates in families with and without early myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 684-692.	2.6	9
149	Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Atherosclerosis, 2017, 256, 134-145.	0.8	9
150	Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 660-666.	2.6	8
151	Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia. Atherosclerosis, 2010, 213, 206-211.	0.8	8
152	The relationship between metabolic syndrome, its components, and the whole-body atherosclerotic disease burden as measured by computed tomography angiography. Atherosclerosis, 2011, 215, 417-420.	0.8	8
153	The role of lipid metabolism in shaping the expansion and the function of regulatory T cells. Clinical and Experimental Immunology, 2022, 208, 181-192.	2.6	8
154	ANMCO Position Paper: diagnosticâ€“therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. European Heart Journal Supplements, 2017, 19, D55-D63.	0.1	7
155	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. Clinical Cardiology, 2018, 41, 1075-1083.	1.8	7
156	ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158679.	2.4	7
157	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	7
158	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. Journal of Clinical Lipidology, 2021, 15, 822-831.	1.5	7
159	The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway. Biomolecules, 2022, 12, 585.	4.0	7
160	Functional rs20417 SNP (â€“765G>C) of Cyclooxygenase-2 Gene Does Not Predict the Risk of Recurrence of Ischemic Events in Coronary Patients: Results of a 7-Year Prospective Study. Cardiology, 2010, 115, 236-242.	1.4	6
161	Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper. Journal of Cardiovascular Medicine, 2021, 22, 609-617.	1.5	6
162	Erythrocyte fatty acid composition and gallstone disease: results of an epidemiological survey. American Journal of Clinical Nutrition, 1987, 46, 110-114.	4.7	5

#	Article	IF	Citations
163	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. Journal of Clinical Medicine, 2021, 10, 886.	2.4	5
164	Elevated Serum Concentrations of Remnant Cholesterol Associate with Increased Carotid Intima-Media Thickness in Children and Adolescents. Journal of Pediatrics, 2021, 232, 133-139.e1.	1.8	5
165	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. Atherosclerosis Plus, 2021, 43, 7-9.	0.7	5
166	Severe coronary and extracoronary atherosclerosis in autosomal recessive hypercholesterolemia detected by whole-body computed tomography angiography. Internal and Emergency Medicine, 2011, 6, 571-573.	2.0	4
167	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
168	Is it Time for Single-Pill Combinations in Dyslipidemia?. American Journal of Cardiovascular Drugs, 2022, 22, 239-249.	2.2	4
169	Lack of association between arterial blood pressure and erythrocyte fatty acid composition in an Italian population sample. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 105-110.	1.2	4
170	Circulating platelet aggregates in an adult population sample relationships with the main coronary risk factors and cardiovascular diseases. Atherosclerosis, 1980, 35, 375-381.	0.8	3
171	Tumor necrosis factor alpha (TNFÎ±) and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL). Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 262-269.	2.6	3
172	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	3.2	3
173	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal Supplements, 2017, 19, D64-D69.	0.1	2
174	Association of Serum Selenium with Selected Cardiovascular Risk Factors. Microchemical Journal, 1995, 51, 170-180.	4.5	1
175	Dyslipidemia and Cardiovascular Risk in Obesity. , 2015, , 121-130.		1
176	Current challenges in the management of patients with familial hypercholesterolemia. Clinical Lipidology, 2013, 8, 217-229.	0.4	0
177	Does liver-derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives. Clinical Lipidology, 2013, 8, 615-618.	0.4	0
178	538â€ƒImpact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospital during COVID-19 pandemic in Italy. European Heart Journal Supplements, 2021, 23, .	0.1	0